Another CD28 construct, KTE-C19 – now developed as axi-cel – designed at the NCI, was successfully employed in patients with refractory diffuse large B cell lymphoma (DLBCL) and indolent B-cell malignancies, showing a response in 12/15 cases, including 8 CR (18). Here, CD28 is linked to diffuse large B-cell lymphoma.